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Since experiments were conducted with high E2 doses, uterine and tumour growth were tested 19 using pellets (MedRods) releasing the low active E1 at a dose as low as of 0.3 μg/day corresponding 20 to approximately 80nM of circulating E1 (see supplemental Figure 1 ). E1 requires concentrations of 21 at least 1-2 magnitudes higher than E2 to elicit similar responses [33] . Data shown in figure refers 22 to the wet weights at humane endpoint (animal sacrifice, six weeks after OVX). E1 was not 23 significantly converted to E2 (measured by LC-MS in these mice) but it induced strong uterine 24 responses and tumour growth that were not distinguishable from E2 treated mice.
